AMONDYS 45 Drug Patent Profile

When do Amondys 45 patents expire, and what generic alternatives are available?

Amondys 45 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-eight patent family members in twenty-five countries.

The generic ingredient in AMONDYS 45 is casimersen. One supplier is listed for this compound. Additional details are available on the casimersen profile page.

DrugPatentWatch^® Generic Entry Outlook for Amondys 45

Amondys 45 was eligible for patent challenges on February 25, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AMONDYS 45

International Patents:	88
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMONDYS 45
What excipients (inactive ingredients) are in AMONDYS 45?	AMONDYS 45 excipients list
DailyMed Link:	AMONDYS 45 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AMONDYS 45

Constraining patent/regulatory exclusivity:

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING

NDA:

213026

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for AMONDYS 45

Drug Class	Antisense Oligonucleotide
Physiological Effect	Increased Protein Synthesis

US Patents and Regulatory Information for AMONDYS 45

AMONDYS 45 is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes

Expired US Patents for AMONDYS 45

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021

International Patents for AMONDYS 45

See the table below for patents covering AMONDYS 45 around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2553104
Cyprus	1111447
Austria	510914
South Korea	102366851

Market Dynamics and Financial Trajectory for AMONDYS 45

Last updated: January 2, 2026

Summary

AMONDYS 45 (casimersen) is a prominent therapeutic agent developed by Sarepta Therapeutics, approved for treating Duchenne Muscular Dystrophy (DMD) with specific genetic mutations. As an exon-skipping antisense oligonucleotide, it targets exon 45 to restore dystrophin expression. This analysis examines market dynamics, regulatory landscape, competitive positioning, financial projections, and growth drivers, providing an authoritative overview for stakeholders and investors.

---

What Is AMONDYS 45?

Parameter	Details
Generic Name	Casimersen
Brand Name	Amondys 45
Mechanism	Antisense oligonucleotide; exon 45 skipping
Indication	DMD patients with confirmed deletion of exon 45 (approximately 8-10% of DMD cases)
Approval Date	February 2021 (FDA)
Manufacturing	Sarepta Therapeutics

---

Market Landscape for DMD Therapies

Prevalence and Unmet Need

Attribute	Data
Global DMD prevalence	~1 in 5,000 male births (~20,000–30,000 cases globally)
Exon 45 deletion prevalence	8–10% of DMD cases (~1,600–3,000 patients globally)
Unmet need	Limited effective therapies for exon-specific mutations; high unmet medical demand

Existing and Pipeline Treatments

Therapeutic Agents	Mechanism & Status	Market Share / Pipeline Stage
Emflaza (deflazacort)	Corticosteroid	Approved; symptomatic management
Vyondys 53 (golodirsen)	Exon 53 skipping	Approved; similar exon-skipping class
SRP-5051 (casimersen conjugate)	Exon 45 skipping	Phase 2/3 trials
Ataluren	Read-through agent	Approved in some markets

Note: Exon-specific exon-skipping drugs target distinct mutation subsets, limiting the total addressable market but offering personalized treatment options.

---

Regulatory and Reimbursement Landscape

Regulatory Milestones

Authority	Status / Date	Comments
FDA	Approved February 2021	First exon 45 skipping therapy
EMA	Under review	Pending similar approval; crucial for European market
Other Markets	Varies by region	Japan, Canada, and emerging markets under consideration

Reimbursement Challenges and Opportunities

• Payers require demonstrated clinical benefits and cost-effectiveness.
• High treatment costs (~$300,000–$400,000 annually) pose reimbursement hurdles.
• Broader adoption facilitated by patient advocacy and health policy initiatives.

---

Market Dynamics: Drivers and Constraints

Key Growth Drivers

Factor	Impact	Details
Personalized medicine trend	High	Tailored exon-skipping therapies address specific genetic mutations, aligning with precision medicine initiatives.
Rare disease incentives	Moderate	Orphan drug status grants benefits like market exclusivity, tax credits, and expedited review.
Pipeline expansion	Positive	Ongoing clinical trials for various exons and combination therapies could expand indications.
Patient advocacy	Significant	Activism supports regulatory approval, funding, and insurance coverage.

Market Constraints

Factor	Impact	Details
Limited addressable population	Negative	Exon 45 deletion comprises only ~8-10% of DMD cases, capping market size.
High treatment costs	Barrier	Costs limit payer willingness and patient access, influencing revenue potential.
Competition from emerging therapies	Risk	New modalities (gene therapy, CRISPR approaches) could threaten exon-skipping niche.
Regulatory scrutiny	Consideration	Demonstrating long-term clinical benefit remains challenging, especially in rare disease populations.

---

Financial Trajectory: Projections and Analysis

Current Revenue and Market Penetration

Year	Estimated Global Sales (USD)	Key Drivers	Notes
2021	~$50 million	Initial launch, early adoption	Limited by exclusive indication and payer hesitancer.
2022	~$150 million	Expanded awareness, payer coverage	Growth fueled by increasing prescriptions.
2023	~$300 million	Market penetration, expanded patient access	Tiered negotiations and expanding clinical data enhance confidence.

Forecast for 2025 and Beyond

Year	Projected Sales (USD)	Assumptions	Growth Rate
2024	~$500 million	Broader approval, reimbursement gains	67% YoY growth from 2023
2025	~$700 million	Increased adoption, pipeline contribution	40% YoY growth

Note: These projections incorporate conservative assumptions about pipeline success, competitive risks, and reimbursement.

Factors Influencing Financial Trajectory

• Market share gains from expanding clinician familiarity.
• Pricing strategies balancing access and profitability.
• Pipeline contributions from supplementary exon-skipping agents.
• Regulatory approvals in Europe and other territories.
• Patient access programs and value-based reimbursement models.

---

Competitive Comparison

Drug	Target Exon	FDA Approval	Estimated U.S. Sales (2023)	Market Cap/DTO	Notes
Amondys 45	Exon 45	2021	~$250 million (est.)	Sarepta: ~$7 billion	First in class for exon 45 skipping
Vyondys 53	Exon 53	2019	~$220 million	Sarepta dominant	Competes in exon 53 subset
Elevidys	Micro-dystrophin gene therapy	2023 (EMA)	Pending	Emerging alternative	Potential disruptor
Others	Various exons	Under trial	Variable	N/A	Pipeline expansion risks

---

Key Challenges and Opportunities

Challenges	Strategies to Address
Limited patient pool	Develop combination approaches targeting multiple exons
Reimbursement hurdles	Demonstrate long-term clinical benefits and cost savings
Competitive threats	Accelerate pipeline for broader mutation coverage

Opportunities	Strategic Actions
Expanding indications	Proactively pursue regulatory approval for additional exon therapies
Global access	Strengthen partnerships to enter emerging markets
Pipeline diversification	Invest in new modalities like gene editing and gene therapy

---

Comparison with Broader Pharmaceutical Trends

Trend	Impact on AMONDYS 45
Personalized therapies	Enhances market relevance for exon-specific drugs; increases valuation
Orphan drug focus	Incentivizes continued R&D despite small markets
Cost-effectiveness debates	Necessitates demonstrating value to payers

---

Key Takeaways

• Limited but Growing Niche: AMONDYS 45 serves a small, genetically defined subset of DMD patients (~8–10%), with a potential global market of approximately 1,600–3,000 patients.
• Revenue Trajectory: Market projections suggest rapid growth, reaching ~$700 million globally by 2025 contingent on approvals and payer acceptance.
• Regulatory and Reimbursement Risks: Demonstrating long-term clinical benefit remains critical; high treatment costs challenge coverage.
• Pipeline and Competition: Upcoming therapies, gene editing, and broader exon-skipping drugs threaten to diversify and disrupt the current niche.
• Strategic Outlook: Success hinges on expanding indications, ensuring payer coverage, and advancing pipeline treatments.

---

Five FAQs

1. What is the primary mechanism of AMONDYS 45?
AMONDYS 45 (casimersen) employs antisense oligonucleotides to induce exon 45 skipping during pre-mRNA splicing, restoring dystrophin production in specific DMD mutations.

2. How many patients are eligible for AMONDYS 45?
Approximately 8–10% of DMD patients with confirmed deletion of exon 45 worldwide, estimated at 1,600–3,000 patients.

3. What are the main barriers to AMONDYS 45's market expansion?
Limited patient population, high treatment costs, reimbursement challenges, and competition from emerging therapies.

4. How does AMONDYS 45 compare to other exon-skipping drugs?
It is the first approved exon 45 skipping therapy, with a narrow indication but significant in its class. Its market share depends on clinician adoption, reimbursement, and pipeline developments.

5. What is the outlook for AMONDYS 45 in the next five years?
Projected to see substantial growth as approvals expand globally, with potential revenue reaching ~$700 million by 2025, provided pipeline success and reimbursement hurdles are managed.

---

References

1. FDA Label for Amondys 45 (casimersen), 2021.
2. Sarepta Therapeutics Annual Reports, 2022–2023.
3. Global DMD Market Analysis, Future Market Insights, 2022.
4. Clinical Trial Data for Casimersen, ClinicalTrials.gov, 2023.
5. Orphan Drug Designation Policy, FDA, 2019.

---

Disclaimer: All projections and data are estimates based on current information, and market conditions are subject to change. Stakeholders should conduct ongoing due diligence.